Calidar has announced the completion of patient enrollment in its first-in-human clinical study evaluating the company’s 4D Mammography system, marking a key milestone in the development of next-generation breast imaging technology.

The investigational system leverages X-ray diffraction to provide molecular-level insights into breast tissue, enabling clinicians to differentiate between benign and malignant lesions with greater precision. By moving beyond conventional structural imaging, the platform aims to improve diagnostic accuracy and reduce unnecessary biopsies.

The study is designed to assess the safety and feasibility of the 4D Mammography system in a clinical setting, while also generating early data on its diagnostic performance. This approach represents a shift toward more advanced, data-rich imaging modalities that can support earlier and more accurate detection of breast cancer.

Breast cancer remains one of the most common cancers worldwide, and limitations in current imaging techniques—particularly in patients with dense breast tissue—continue to present challenges in early detection. Technologies that offer enhanced tissue characterization at the molecular level are increasingly being explored to address these gaps.

Completion of enrollment signals progress toward broader clinical validation and potential regulatory pathways. As the study advances, further data will be critical in determining the system’s clinical utility and its role in future diagnostic workflows.